COMMUNIQUÉS West-GlobeNewswire

-
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
31/03/2025 -
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
31/03/2025 -
Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives
31/03/2025 -
BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)
31/03/2025 -
Glucofreedom Drops Reviews (EXPOSED) Gluco Revive BloodSugar Control ORDER NOW!
31/03/2025 -
SBC Medical Accelerates Multi-Brand Strategy with ‘SBC NEO Skin Clinic’ Expansion
31/03/2025 -
AAVantgarde and TIGEM Publish Groundbreaking Research in Science Advances
31/03/2025 -
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
31/03/2025 -
NANOBIOTIX publiera ses résultats financiers et opérationnels de l’exercice 2024 le 2 avril 2025
31/03/2025 -
BioVersys Announces Important BV100 Patent Granted by Chinese Patent Office
31/03/2025 -
Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA
31/03/2025 -
Valneva soumet à la MHRA une demande d’élargissement de l’indication aux adolescents pour son vaccin contre le chikungunya IXCHIQ®
31/03/2025 -
Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis
31/03/2025 -
Opthea Announces Decision to Discontinue Wet AMD Trials
31/03/2025 -
First Three Children to Commence Treatment With Ryoncil®
31/03/2025 -
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
30/03/2025 -
Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress
30/03/2025 -
Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk
29/03/2025 -
ProDentim Reviews (EXPOSED): Why 75,000+ Americans Are Replacing Mouthwash with This ProDentim Chewable Tablet
29/03/2025
Pages